Loading…
Loading…
ISCNF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ISCNF and 80,000+ other tickers.
See exactly how ISCNF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ISCNF and 80,000+ other tickers.
Isracann Biosciences Inc., operating with its subsidiary companies, focuses on the growth and supply of medical-grade cannabis throughout Israel. The firm also dedicates resources to establishing new cultivation infrastructure. Additionally, it ships its products internationally to Germany. The company rebranded to Isracann Biosciences Inc. in October 2019, having previously been known as Atlas Blockchain Group Inc. Founded in 2010, its corporate headquarters are situated in Vancouver, Canada.
Toronto, Ontario--(Newsfile Corp. - le 4 septembre/September 2024) - The common shares of Isracann Biosciences Inc. will be delisted from the CSE at market close today, September 4, 2024. Isracann Biosciences Inc. is currently suspended.
Nick Gastevich, one of our favorite commenters on Seeking Alpha, returns to the show to catch us up on the state of cannabis investing. Wave of new states legalizing cannabis now especially important in the face of long federal delays.
VANCOUVER, British Columbia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer announces it has implemented a warrant exercise incentive program designed to encourage exercise of up to 20,574,216 of its outstanding share purchase warrants expiring on September 30, 2021 (the “Warrants”). The Company will amend the exercise price of the Warrants from $1.02 per common share of the Company (each, a “Share”) to $0.30 per Share, subject to acceleration. If, for any ten consecutive trading days during the unexpired term of the Warrants the closing price of the Shares on the Canadian Securities Exchange exceeds $0.375, then, upon the Company sending to the holders of the Warrants (the “Warrantholders”) notice of acceleration of the expiry date by way of a news release announcing such accelerated expiry date, the Warrants will only be exercisable for a period of 30 days following the date of such news release.